Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options

Winfried Randerath, Oana Claudia Deleanu, Sofia Schiza, Jean-Louis Pepin
European Respiratory Review 2019 28: 190084; DOI: 10.1183/16000617.0084-2019
Winfried Randerath
1Institute of Pneumology at the University of Cologne, Bethanien Hospital, Clinic for Pneumology and Allergology, Centre of Sleep Medicine and Respiratory Care, Solingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: randerath@klinik-bethanien.de
Oana Claudia Deleanu
2University of Medicine and Pharmacy “Carol Davila” and Institute of Pneumology “Marius Nasta” Bucharest, Bucharest, Romania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Schiza
3Sofia Schiza, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Louis Pepin
4Laboratoire du sommeil explorations fonctionnelle Respire, Centre Hospitalier Universitaire Grenoble, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Illustration of the pathophysiological approach to treatment of sleep disordered breathing. Continuous positive airway pressure or expiratory positive airway pressure stabilise the obstructive component of the upper airways; variable pressure support or mandatory breaths counterbalance the overshoot and undershoot of ventilation due to brainstem disturbances; and reduction in tidal volume and minute ventilation require mechanical ventilation.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    The respiratory system is composed of three components, which have been described as a loop gain. Imbalance of the loop gain may lead to a vicious circle of overshoot and undershoot of the ventilation: any inadequate increase of the ventilation induces hypocapnia; hypocapnia dampens the carbon dioxide-sensitive chemoreceptors, leading to a dampening of the inspiratory impulses of the brain stem. As a consequence, minute ventilation (generated from the plant gain) is reduced, leading to hypoxia; hypoxia stimulates the chemoreceptors and consecutively respiratory drive.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    The figure shows the approaches of various treatment options on the loop gain. Oxygen (O2) supply increases the alveolar O2 concentration and avoids hypoxic stimulation of the chemoreceptors. In addition, it may influence myocardial function. Carbon dioxide (CO2) plays a major role in the pathophysiology of periodic breathing. The application of CO2 by rebreathing or external supply elevates the arterial CO2 tension above the apnoea threshold and impedes central apnoeas. Drugs may influence respiratory drive in the brainstem. Some pharmaceutical influences on arousability, sleep stages and sleep efficiency can stabilise respiration or shift sleep stages from non-rapid eye movement (REM) stages I and II to slow-wave or REM sleep. CPAP: continuous positive airway pressure; BIPAP: bilevel positive airway pressure.

Tables

  • Figures
  • TABLE 1

    Studies on adaptive servoventilation since the publication of SERVE-HF

    Study/authors, year [reference]DesignPopulationInterventionPrimary outcomeMedian follow-upResults
    FACE study, 2016 [50]Prospective multicentre observational cohort
    France
    Up to January 31, 2013
    CHF with reduced LVEF (HFrEF <40%), mid-range (HFmrEF 40–49%), preserved (HFpEF >50%)361 CHF patients with CSA eligible for ASV therapy (n=258) versus controls# (n=133) refused/not compliant with ASV (<3 h per night)
    (ResMed, AutoSet CS) 66% compliant to ASV therapy
    All-cause death, hospitalisation for worsening heart failure, heart transplant or ventricular assist device21.6 monthsASV improved prognosis in HFmEF in non-ischaemic heart failure; trend to increase in event rate in HFmrEF in ischaemic heart disease; improved prognosis in HFpEF CHF with severe desaturations
    CAT-HF study, 2017 [51]Prospective, randomised, controlled, multicentre clinical trial
    United States and Germany
    2013–2015
    Hospitalised heart failure (HFrEF >45% or HFpEF ≥45%) and SDB (OSA or CSA) with AHI ≥15 events·h−1 via polygraphy126 out of 215 patients assigned on ASV plus optimised medical therapy (n=65) versus optimised medical therapy alone (control) (n=61)Composite global rank score (death, CV hospitalisations, and percentage changes in 6-min walk distance)
    Secondary end-points: sleep apnoea parameters, functional capacity, cardiovascular and all-cause death, days alive and out of the hospital, biomarkers, QoL, sleep parameters, imaging parameters and NYHA functional class
    6 monthsNeutral
    No improvement in 6-month cardiovascular outcomes; however, a positive effect of ASV in patients with HFpEF
    Study was stopped after publication of SERVE-HF
    Imamura et al., 2016 [52]Case–control study
    Tokyo, Japan
    2008–2014
    Heart failure NYHA III or IV (71% NYHA IV, LVEF 33±17%) with ASV irrespective of SDB85 patients receiving ASV 1 month versus guideline-directed medical therapies
    (AutoSet-CS; ResMed, Sydney, Australia) with full face mask (ResMed)
    All-cause mortality and cardiac deaths2-year follow-upContinued ASV significantly lowered all-cause mortality and cardiac death rate
    Hetland et al., 2016 [53]Retrospective observational study
    Østfold, Norway
    2007–2012
    Heart failure NYHA class II–IV, LVEF ≤45%; CSR pattern ≥25% of sleeping time and dominant central sleeping pattern via polygraphy75 patients treated with ASV (n=31 with ASV for >3–18 months versus n=44 control)
    (AutoSet-CS)
    Mortality and hospital admission of any cause and number of days in hospital in total18 monthsASV did not significantly affect CV death or combined CV death or hospital admissions after 18 months; trend toward better CV event-free survival for ASV usage
    Bordier and Lataste, 2019 [54]Retrospective study
    2006–2018
    Patient from the sleep unit of the CV department treated with ASV for sleep apnoea (C/M/O apnoeas via PG)32 patients with ASV
    8 deaths
    CV mortalitySurvivalCV deaths not predominant
    No relationship between sleep apnoea or ASV and death
    Mansukhani et al., 2019 [55]Population-based study, using the Rochester Epidemiology Project databaseCSA (AHI 41.6±26.5 events·h−1), with ASV therapy (65% ≥4 h per night on ≥70% nights in their first month), and had ≥1 month of clinical data before and after ASV initiation309 CSA patients under ASV versus healthcare utilisationRates of hospitalisations, emergency department visits, outpatient visits and medications prescribed per year (mean±sd)2 years pre- and post-ASV initiationASV did not change healthcare utilisation
    ADVENT-HF trial, recruiting [56]Multicentre, multinational, randomised, parallel-group, open-label trial
    Canada
    Chronic HFrEF (≤45%) and SDB (OSA or CSA) with AHI ≥15 events·h−1 via PSGEstimated n>800, still recruiting 524 patients (31% CSA, 69% OSA) randomised until February 2018 on medical therapy alone or ASV (AutoSet-CS) with nasal maskAll-cause mortality, first hospitalisation for CV diseases, new-onset atrial fibrillation/flutter requiring anticoagulation but not hospitalisation or implantable cardioverter-defibrillator shock not requiring hospitalisationEvery 6 monthsAwaited

    ASV studies with mortality as primary outcome. The table summarises the results of additional studies on ASV in heart failure and CSA. Methodologies incompletely describe the types of masks and ASV devices used, sleep study, algorithm of titration and compliance to the device. Only one study (FACE) stratified patients in relation to the severity of HFrEF. CHF: chronic heart failure; LVEF: left ventricular ejection fraction; HFrEF: heart failure with reduced ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure with preserved ejection fraction; CSA: central sleep apnoea; ASV: adaptive servoventilation; SDB: sleep disordered breathing; OSA: obstructive sleep apnoea; AHI: apnoea–hypopnoea index; CV: cardiovascular; QoL: quality of life; NYHA: New York Heart Association; CSR: Cheyne–Stokes respiration.

    PreviousNext
    Back to top
    View this article with LENS
    Vol 28 Issue 153 Table of Contents
    European Respiratory Review: 28 (153)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options
    Winfried Randerath, Oana Claudia Deleanu, Sofia Schiza, Jean-Louis Pepin
    European Respiratory Review Sep 2019, 28 (153) 190084; DOI: 10.1183/16000617.0084-2019

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options
    Winfried Randerath, Oana Claudia Deleanu, Sofia Schiza, Jean-Louis Pepin
    European Respiratory Review Sep 2019, 28 (153) 190084; DOI: 10.1183/16000617.0084-2019
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • Abstract
      • Introduction
      • CSA and periodic breathing: definition and characterisation
      • Pathophysiology
      • Challenges in managing CSA/periodic breathing in chronic heart failure with reduced ejection fraction
      • Is periodic breathing in CHF a unique entity?
      • Conclusion
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF

    Subjects

    • Sleep medicine
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Insomnia management in sleep disordered breathing
    • Restless leg syndrome in the context of SDB comorbidity
    Show more Sleep and Breathing Conference Review

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERR

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising
    • Sponsorship

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 0905-9180
    Online ISSN: 1600-0617

    Copyright © 2023 by the European Respiratory Society